Oppenheimer Raises PT to $48 on HCA Inc. and Reiterates Outperform Rating

Oppenheimer analyst Michael Wiederhorn published a report on HCA Inc.

that reiterated its Outperform rating and raised the price target from $43 to $48. Oppenheimer reported that, “Our 12- to 18-month price target is $48 per share, or an average of 7x '14E EBITDA of $6.8B, which is a discount to the historical industry average of 8.5X. We believe this discount is even more conservative when considering it does not include any potential upside to earnings from healthcare reform in 2015 and 2016.” Shares of HCA Inc. closed at $38.56 on Thursday.